Pharmaceuticals
EcoSupp listens, learns, and delivers
Israeli health officials call for sanctions on anti-vaxxers as flu morbidity rate rises
Israel's biotech moment: How science, data, and geopolitics are converging - opinion
From Auschwitz to Dachau: How a pharmacist became central to Nazi camp medical crimes - study
After turbulent years, Teva CEO Schultz forecasts stability
Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.
86-year-old Copaxone creator has no intention of slowing down
When it comes to being excited by experiments, age is simply not a factor for 86-year-old Prof. Ruth Arnon, co-creator of multiple sclerosis drug Copaxone.
Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv
Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.
Tufts University to remove Sackler name from buildings and programs
Family has come under fire for their central role in American opioid crisis
Calling Dr. Fischer
Healthcare has always been a part of my home.
![Healthcare and technology [Illustrative]](https://images.jpost.com/image/upload/f_auto,fl_lossy/q_auto/c_fill,g_faces:center,h_194,w_290/432799 "Healthcare and technology [Illustrative]")
Teva shares surge amid hopes of $23 billion opioid claims settlement
Teva stocks also closed up 8.67% on the New York Stock Exchange on Monday amid growing optimism.
Teva proposes $15 billion deal to settle opioid claims
The proposed settlement comes only days ahead of a landmark federal trial in Cleveland, Ohio, against the company and five drug distributors.
Sackler family reaped up to $13 billion from OxyContin maker
The wealthy Sacklers received the money from Purdue during an unspecified time frame, according to court documents and portions of a deposition filed in the drugmaker’s bankruptcy proceedings.
‘Big shortage of pharmacists’ in Israel as deficit grows
Approximately 7,000 licensed pharmacists in the country, but only an estimated 5,000 who are practicing
OxyContin maker Purdue Pharma files for bankruptcy protection
Purdue's board met Sunday evening to approve the long-expected bankruptcy filing, which the company is pursuing to restructure under terms of a proposal to settle the widespread litigation.
